EPO--one year later. Part II. Balancing the costs and benefits.
Blagg
C
C
D003362:Cost-Benefit Analysis / Q000191:economics; D003365:Costs and Cost Analysis / Q000191:economics; D004921:Erythropoietin / Q000627:therapeutic use*; D006801:Humans; D007676:Kidney Failure, Chronic / Q000191:economics / Q000628:therapy; D006435:Renal Dialysis / Q000191:economics
D004921:Erythropoietin